FDA warned GeroNova Research that disease claims on its Amazon store and social media make its carnitine and R-lipoic acid supplements unapproved, misbranded drugs.
What happened
FDA reviewed GeroNova's Amazon.com store and its Facebook and Twitter pages from September to October 2021; the social media pages send consumers to the company website, which sends them to Amazon to buy. FDA quoted posts and product pages linking carnitine and R-lipoic acid to diabetes, depression, Parkinson's disease, liver disease, heart disease and neuropathy. Because the products are marketed for treating disease, FDA treats them as drugs, not supplements.
What FDA found
The company's website and social media posts claim the products diagnose, treat, cure or prevent disease, which legally makes them drugs.
Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]The products are not generally recognized as safe and effective for these uses, so they are "new drugs" and were sold without FDA approval.
Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and 355(a)]The products carry no adequate directions for use, because the diseases they are pitched for cannot be safely self-treated without a licensed practitioner.
Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Selling these misbranded drugs across state lines violates the Act.
Section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.
Who should pay attention
- supplement brands that make health claims on Amazon listings
- companies whose social media posts link to product sales pages
- marketing and regulatory reviewers for dietary supplement sellers
This is a summary. Read the original letter on fda.gov.